Trials / Unknown
UnknownNCT02977897
Fecal Calprotectin Levels in Mycophenolate Mofetil Induced Diarrhea and Treatment With Octreotide
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 10 (estimated)
- Sponsor
- University Health Network, Toronto · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
Prospective, observational pilot study of ten post-transplant patients presenting with diarrhea while taking Mycophenolate Mofetil (MMF). These patients will undergo a standard workup to confirm MMF induced diarrhea. A stool fecal calprotectin will be measured to determine if it may be helpful in confirming the diagnosis of MMF associated diarrhea. Once the diagnosis is confirmed, the patients will then be treated with a short course of subcutaneous Octreotide which has been shown to cure this type of diarrhea.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Octreotide Acetate | Octreotide 100mcg SC q12h for 5 days |
Timeline
- Start date
- 2017-01-01
- Primary completion
- 2017-11-01
- First posted
- 2016-11-30
- Last updated
- 2016-11-30
Locations
1 site across 1 country: Canada
Source: ClinicalTrials.gov record NCT02977897. Inclusion in this directory is not an endorsement.